Shopping Cart
Remove All
Your shopping cart is currently empty
BEN-28010
Copy Product Info
🥰Excellent
Synonyms:
Catalog No. T217829 Copy Product Info
🥰Excellent
BEN-28010 is a selective, orally bioavailable CHK1 inhibitor that can cross the blood-brain barrier, featuring an IC50 of 4.0 nM. This compound acts as a radiosensitizer and demonstrates antitumor activity in glioblastoma (GBM) models. BEN-28010 is applicable for research related to glioblastoma.
BEN-28010
Cas No. 3033961-38-2
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | BEN-28010 is a selective, orally bioavailable CHK1 inhibitor that can cross the blood-brain barrier, featuring an IC50 of 4.0 nM. This compound acts as a radiosensitizer and demonstrates antitumor activity in glioblastoma (GBM) models. BEN-28010 is applicable for research related to glioblastoma. |
| Targets & IC50 | Chk1:4.0 nM |
| In vitro | BEN-28010 is a potent inhibitor of recombinant CHK1 kinase, with an IC50 of 4.0 nM. It inhibits CHK1 activity in SW620 cells with an IC50 of 0.45 μM. BEN-28010 also reduces the viability of p53 mutant LN-18 cells with an efficacy (IC50 0.14 ± 0.01 μM) that is 24 times greater than that for p53 wild-type A172 cells (IC50 3.3 ± 0.15 μM). Additionally, BEN-28010 enhances the cytotoxic effects of ionizing radiation on GBM stem cells, achieving an IC50 of 0.62 μM following 3 Gy IR treatment. The compound demonstrates favorable in vitro ADME properties and selectivity, including high CHK1 selectivity over the kinome and CHK2, low arrhythmia risk, minimal CYP interaction, high permeability, and low efflux mediated by MDR1 and BCRP. |
| In vivo | BEN-28010 (50-100 mg/kg; orally; administered every other day for 10 consecutive days) demonstrates statistically significant tumor growth inhibition both as a standalone treatment and in combination with IR in subcutaneous LN229 glioblastoma (GBM) xenografts. |
| Molecular Weight | 374.44 |
| Formula | C20H22N8 |
| Cas No. | 3033961-38-2 |
| Smiles | N(C1=CN(C=N1)C2=CC=C(C=C2)N3C[C@H](N(C)C)CC3)C=4C=NC(C#N)=CN4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: BEN-28010 in vivo | BEN-28010 in vitro | BEN-28010 formula | BEN-28010 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.